Logo image of KPRX

KIORA PHARMACEUTICALS INC (KPRX) Stock Fundamental Analysis

NASDAQ:KPRX - Nasdaq - US49721T5074 - Common Stock - Currency: USD

3.47  -0.04 (-1.14%)

After market: 3.4101 -0.06 (-1.73%)

Fundamental Rating

4

Overall KPRX gets a fundamental rating of 4 out of 10. We evaluated KPRX against 194 industry peers in the Pharmaceuticals industry. KPRX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. KPRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year KPRX has reported negative net income.
In the past year KPRX had a positive cash flow from operations.
KPRX had negative earnings in each of the past 5 years.
KPRX had a negative operating cash flow in each of the past 5 years.
KPRX Yearly Net Income VS EBIT VS OCF VS FCFKPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

With an excellent Return On Assets value of 14.41%, KPRX belongs to the best of the industry, outperforming 97.30% of the companies in the same industry.
KPRX has a better Return On Equity (18.48%) than 92.43% of its industry peers.
With an excellent Return On Invested Capital value of 15.73%, KPRX belongs to the best of the industry, outperforming 92.97% of the companies in the same industry.
Industry RankSector Rank
ROA 14.41%
ROE 18.48%
ROIC 15.73%
ROA(3y)-78.75%
ROA(5y)-71.97%
ROE(3y)-142.32%
ROE(5y)-129.96%
ROIC(3y)N/A
ROIC(5y)N/A
KPRX Yearly ROA, ROE, ROICKPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K 2K 3K 4K

1.3 Margins

With an excellent Profit Margin value of 34.64%, KPRX belongs to the best of the industry, outperforming 96.76% of the companies in the same industry.
With an excellent Operating Margin value of 43.47%, KPRX belongs to the best of the industry, outperforming 97.30% of the companies in the same industry.
Industry RankSector Rank
OM 43.47%
PM (TTM) 34.64%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KPRX Yearly Profit, Operating, Gross MarginsKPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K -80K

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, KPRX has less shares outstanding
Compared to 5 years ago, KPRX has more shares outstanding
KPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KPRX Yearly Shares OutstandingKPRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
KPRX Yearly Total Debt VS Total AssetsKPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -2.42, we must say that KPRX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.42, KPRX perfoms like the industry average, outperforming 42.16% of the companies in the same industry.
KPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -2.42
ROIC/WACCN/A
WACCN/A
KPRX Yearly LT Debt VS Equity VS FCFKPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M -10M

2.3 Liquidity

KPRX has a Current Ratio of 8.97. This indicates that KPRX is financially healthy and has no problem in meeting its short term obligations.
KPRX has a Current ratio of 8.97. This is in the better half of the industry: KPRX outperforms 79.46% of its industry peers.
KPRX has a Quick Ratio of 8.97. This indicates that KPRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.97, KPRX is in the better half of the industry, outperforming 79.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.97
Quick Ratio 8.97
KPRX Yearly Current Assets VS Current LiabilitesKPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 94.62% over the past year.
EPS 1Y (TTM)94.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KPRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.79% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y103.11%
EPS Next 2Y38.21%
EPS Next 3Y24.04%
EPS Next 5Y14.79%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KPRX Yearly Revenue VS EstimatesKPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
KPRX Yearly EPS VS EstimatesKPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -2K -4K -6K -8K -10K

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

KPRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KPRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KPRX Price Earnings VS Forward Price EarningsKPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

KPRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. KPRX is cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 1.27
EV/EBITDA -6
KPRX Per share dataKPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

A more expensive valuation may be justified as KPRX's earnings are expected to grow with 24.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.21%
EPS Next 3Y24.04%

More info and screens

0

5. Dividend

5.1 Amount

KPRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KIORA PHARMACEUTICALS INC

NASDAQ:KPRX (2/21/2025, 8:00:02 PM)

After market: 3.4101 -0.06 (-1.73%)

3.47

-0.04 (-1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)03-24 2025-03-24/amc
Inst Owners37.31%
Inst Owner Change-14.13%
Ins Owners2.16%
Ins Owner Change3.93%
Market Cap10.41M
Analysts82.5
Price Target10.2 (193.95%)
Short Float %0.68%
Short Ratio0.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.7%
Min EPS beat(2)-3.94%
Max EPS beat(2)39.35%
EPS beat(4)2
Avg EPS beat(4)172.44%
Min EPS beat(4)-10.1%
Max EPS beat(4)664.47%
EPS beat(8)5
Avg EPS beat(8)80.24%
EPS beat(12)6
Avg EPS beat(12)33.73%
EPS beat(16)9
Avg EPS beat(16)26.74%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)8.33%
EPS NQ rev (3m)24.55%
EPS NY rev (1m)21.26%
EPS NY rev (3m)-35.78%
Revenue NQ rev (1m)50%
Revenue NQ rev (3m)50%
Revenue NY rev (1m)1.49%
Revenue NY rev (3m)1.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.65
P/FCF 1.27
P/OCF 1.26
P/B 0.35
P/tB 0.45
EV/EBITDA -6
EPS(TTM)-2.15
EYN/A
EPS(NY)-2.54
Fwd EYN/A
FCF(TTM)2.73
FCFY78.61%
OCF(TTM)2.74
OCFY79.1%
SpS5.34
BVpS10.01
TBVpS7.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 14.41%
ROE 18.48%
ROCE 19.91%
ROIC 15.73%
ROICexc 92.52%
ROICexgc N/A
OM 43.47%
PM (TTM) 34.64%
GM N/A
FCFM 51.08%
ROA(3y)-78.75%
ROA(5y)-71.97%
ROE(3y)-142.32%
ROE(5y)-129.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 117.81%
Profit Quality 147.46%
Current Ratio 8.97
Quick Ratio 8.97
Altman-Z -2.42
F-Score8
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.89%
EPS Next Y103.11%
EPS Next 2Y38.21%
EPS Next 3Y24.04%
EPS Next 5Y14.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y162.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y172.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y173.39%
OCF growth 3YN/A
OCF growth 5YN/A